Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: A study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

1. Ruiz-Pinto, S.
2. Martin, M.
3. Pita, G.
4. Caronia, D.
5. De La Torre-Montero, J.C.
6. Moreno, L.T.
7. Moreno, F.
8. Garciá-Saénz, J.A.
9. Benítez, J.
10. González-Neira, A.